Every Form 4 that TEVOGEN INC (TVGN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TVGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TVGN filings page.
Sordillo Victor J. reported acquisition or exercise transactions in this Form 4 filing.
Tevogen Bio Holdings Inc. director Victor J. Sordillo received a grant of 40,000 shares of restricted common stock at no cost under the 2024 Omnibus Incentive Plan. The award vests in three equal installments tied both to service-based anniversaries and aggregate revenue milestones of $50 million, $100 million, and $150 million since the grant date, conditioned on his continued service. Following this grant, Sordillo directly holds 51,539 shares of Tevogen Bio common stock.
Saadi Ryan H. reported acquisition or exercise transactions in this Form 4 filing.
Tevogen Bio Holdings Inc. disclosed that Chief Executive Officer Ryan H. Saadi received a grant of 1,220,000 shares of restricted common stock at $0.0000 per share under the 2024 Omnibus Incentive Plan. The award will vest in four equal annual installments commencing on July 10, 2033, contingent on his continued service. Following the grant, he holds 3,705,689 shares directly, plus 3,878 shares indirectly through his wife.
PODLOGAR SUSAN M reported acquisition or exercise transactions in this Form 4 filing.
Tevogen Bio Holdings Inc. granted director Susan M. Podlogar 40,000 shares of restricted common stock at no cash cost under its 2024 Omnibus Incentive Plan. The award vests in three equal installments, each requiring both a service condition and company revenue milestones of $50 million, $100 million, and $150 million in aggregate revenue since the grant date. Following this grant, Podlogar directly holds 48,678 shares of common stock.
Patton Curtis L. reported acquisition or exercise transactions in this Form 4 filing.
Tevogen Bio Holdings Inc. director Curtis L. Patton received a grant of 40,000 shares of restricted common stock under the company’s 2024 Omnibus Incentive Plan. The award vests in three equal installments, each tied to both a service requirement and revenue milestones of $50 million, $100 million, and $150 million of aggregate revenue since the grant date. Following this grant, Patton directly holds 64,192 shares of common stock.
Goh Keow Lin reported acquisition or exercise transactions in this Form 4 filing.
Tevogen Bio Holdings Inc. director Goh Keow Lin received a grant of 40,000 shares of restricted common stock under the 2024 Omnibus Incentive Plan. The award vests in three equal installments upon the earlier of specified anniversaries of the grant date and the company reaching aggregate revenue milestones of $50 million, $100 million, and $150 million, subject to continued service. Following this grant, the director holds 48,678 common shares directly.
Feike Jeffrey L. reported acquisition or exercise transactions in this Form 4 filing.
Tevogen Bio Holdings Inc. director Jeffrey L. Feike received a grant of 40,000 shares of restricted common stock at $0.00 per share under the 2024 Omnibus Incentive Plan. The award vests in three equal installments tied to service-based anniversaries and aggregate revenue thresholds of $50 million, $100 million, and $150 million since the grant date. Following this grant, Feike directly holds 56,435 common shares.
Desai Kirti reported acquisition or exercise transactions in this Form 4 filing.
Tevogen Bio Holdings Inc. granted its Chief Financial Officer, Kirti Desai, 40,000 shares of restricted common stock at $0.00 per share under the 2024 Omnibus Incentive Plan. The award vests in three equal installments upon specified combinations of service anniversaries and aggregate revenue targets of $50 million, $100 million, and $150 million, subject to continued service. Following this grant, Desai directly holds 242,983 shares of common stock.
Tevogen Bio Holdings Inc. officer Neal Flomenberg reported selling a total of 972 shares of common stock in three open-market transactions on March 10, 11, and 13, 2026. The shares were sold at weighted average prices of about $7.75, $7.26, and $6.40, with actual trades in ranges from $7.25–$7.33 and $6.39–$6.74.
According to the filing, these sales were made solely to satisfy tax obligations arising from the vesting and settlement of restricted stock units and were not made at Flomenberg’s discretion. After these transactions, he directly holds 76,940 shares of Tevogen Bio common stock.
Tevogen Bio Holdings Inc.'s Chief Financial Officer reported gifting 300,000 shares of common stock in a recent insider transaction.
The filing states that 100,000 shares were donated to Shrimad Rajchandra Love and Care USA, Inc. and 200,000 shares to Shrimad Rajchandra Mission Dharampur (USA), Inc., both described as charitable entities. Following these gifts, the reporting person beneficially owns 10,149,186 shares of Tevogen Bio common stock directly.
Tevogen Bio Holdings Inc. reported that a company insider who is a director, chief executive officer and 10% owner gifted 460,000 shares of common stock on December 11, 2025. The transaction was coded as a gift at a reported price of $0 per share.
The gift consisted of 230,000 shares to Shrimad Rajchandra Love and Care USA, Inc. and 230,000 shares to Warren Township Honorary P.B.A., Inc., both described as charitable entities. After this transaction, the reporting person beneficially owned 124,334,453.322 shares directly and 193,924 shares indirectly through a spouse.